Published: Thu, October 12, 2017
Economy | By Annette Adams

K2M Group Holdings, Inc. (NASDAQ:KTWO), JPMorgan Chase & Co. (NYSE:JPM)


The 12-month price target is $20.43 with zero analysts rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 firms rating the stock a sell. Therefore 91% are positive. If the published price targets set by The Procter & Gamble Company analysts have any power to influence the stock's share price, the highest price target set for PG is $106.

According to 10 analysts K2M Group Hldngs Cmn (NASDAQ:KTWO)'s price will reach at $25.5 during 52 weeks. RBC Capital Markets maintained K2M Group Holdings Inc (NASDAQ:KTWO) on Friday, September 22 with "Buy" rating. The rating was initiated by RBC Capital Markets on Monday, October 10 with "Outperform". Cytori Therapeutics (NASDAQ:CYTX) has a market capitalization of $15.66 Million and most recently 27.96 Million outstanding shares have been calculated. The rating was maintained by RBC Capital Markets on Tuesday, July 18 with "Buy". The firm earned "Buy" rating on Tuesday, July 11 by Oppenheimer.

ValuEngine cut shares of K2M Group Holdings, Inc.

Analysts have a mean recommendation of 2.50 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range).

09/22/2015 - UBS began new coverage on K2M Group Holdings, Inc. giving the company a "buy" rating.

K2M Group Holdings (NASDAQ:KTWO) last announced its earnings results on Tuesday, August 1st. The stock has "Buy" rating by Oppenheimer on Wednesday, August 2. Share performance for the month is now at 19.36%.

The Procter & Gamble Company has a beta of 1.44, offering the possibility of a higher rate of return, but also posing more risk. The stock decreased 1.74% or $0.78 during the last trading session, reaching $44.09. Prospector Partners Llc, a Connecticut-based fund reported 72,110 shares.

Since January 1, 0001, it had 0 insider purchases, and 1 insider sale for $153,559 activity.

5,078K shares changed hands in the last trading session.

Short traders are more bearish on shares of the company if you consider the uptick in short interest.

They now have a $23 price target on K2M Group Holdings (NASDAQ:KTWO). It has outperformed by 1.07% the S&P500. During last 3 month period, 0.08% of total institutional ownership has changed in the company shares. BDN's profit will be $61.31 million for 12.72 P/E if the $0.35 EPS becomes a reality. The medical device company reported ($0.21) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.22) by $0.01. ValuEngine cut shares of K2M Group Holdings from a hold rating to a sell rating in a report on Tuesday. For the quarter, shares have been noted at 15.69%. On average, equities analysts expect that K2M Group Holdings will post ($0.82) EPS for the current year. K2M Group Holdings Inc (NASDAQ:KTWO) has risen 113.03% since October 11, 2016 and is uptrending. It has outperformed by 96.33% the S&P500.

K2M Group Holdings, Inc.is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The company has market cap of $799.52 million. The Company's solutions are focused on achieving three-dimensional Total Body Balance.

The company's Average Earnings Estimate for the Current Fiscal quarter is $-0.16, according to consensus of 10 analysts. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.

Like this: